Abstract
Herein we report the construction of a nanoparticle-based drug delivery system which targets a key regulator in tumour angiogenesis. We exploit a Variable New Antigen Receptor (VNAR) domain, conjugated using site-specific chemistry, to direct poly lactic acid-co-glycolic acid-polyethylene glycol (PLGA-PEG) nanoparticles to delta like canonical Notch ligand 4 (DLL4). The importance of site-specific chemistry is demonstrated.
Original language | English |
---|---|
Pages (from-to) | 7671-7674 |
Journal | Chemical Communications |
Volume | 55 |
Issue number | 53 |
DOIs | |
Publication status | Published - 27 Jun 2019 |